Introduction
============

Most protein-based toxins have the potential to be developed as a toxin moiety in immunotoxin-based drugs ([@ref-2]; [@ref-6]; [@ref-21]; [@ref-20]; [@ref-25]; [@ref-27]; [@ref-19]). These toxin moieties generally need to internalize and translocate to the cytosol in order to achieve its cytotoxic effects, most of which function by enzymatically inhibiting protein synthesis ([@ref-31]; [@ref-32]). However, the size of toxins is generally a major hurdle, which leads to poor tissue penetration. To overcome this problem, another class of relatively small sized toxins has been explored. Cnidarian actinoporin is a potential toxin moiety candidate for immunotoxins owing to its relatively small size (18.5--20 kDa), thus allowing increased penetration and lower immunogenicity ([@ref-31]; [@ref-17]). Additionally, extreme stability towards proteolytic degradation also makes them good toxin conjugate candidates ([@ref-30]).

Actinoporins depend on the recognition of sphingomyelin (SM) in the cell membrane in order to lyse and permeabilize specific cell types ([@ref-26]). It is capable of forming pores that disrupt ion gradients, which can cause osmotic swelling, leading to cell death. Few studies have proven that the Equinatoxin II (EqtII) toxin derived from sea anemone *Actinia equina* showed significant toxicity against Erlich ascites tumours, L1210 leukemia cells and diploid lung fibroblast of the Chinese hamster. It is a potent inhibitor of papain-like cysteine proteinase and aspartic proteinase cathepsin D, which is normally found in breast cancer and nerve-related diseases ([@ref-12]). Another study also reported anti-butyrylcholinestrasic activity from toxins derived from the Mediterranean jellyfish *Pelagia noctiluca,* which is useful in treating Alzheimer's disease and senile dementia ([@ref-12]). The first use of actinoporins as part of immunotoxins to kill cancerous cells involves the hemolytic fraction from the sea anemone *Stichodactyla helianthus* fused to mAbs to target carcinoembryonic antigens (CEA) ([@ref-3]). Unfortunately, results showed ineffective killing towards targeted cells due to excessive binding of free antibodies ([@ref-30]). While actinoporins have shown encouraging results in recent studies, its non-specific binding capability remains a major challenge when it comes to targeted therapeutic applications.

Multiple steps are involved in the mechanism of pore formation by actinoporins. The process begins when actinoporins attaches itself to a sphingomyelin associated membrane where the phosphocholine (POC) binding site plays a critical role. Then, the N-terminal translocates to the lipid-water interface where it undergoes conformational changes, detaches from the protein and inserts into the lipid membrane. Subsequently, 3 to 4 actinoporins oligomerize within the plasma membrane and a functional pore is then created by chemical cross linking of the N-terminal α-helix ([@ref-14]; [@ref-10]; [@ref-8]; [@ref-24]; [@ref-11]; [@ref-29]). A recent study showed the insertion of negative charged amino acids at the N-terminal region of *Hydra* actinoporin-like toxin-1 (HALT-1) strongly reduces the cytolytic activity of the toxin, presumably due to abrogation of its binding properties ([@ref-14]).

Venom from *Hydra magnipapillata's* nematocysts has strong hemolytic and phospholipase properties, which often cause long lasting paralysis and even death ([@ref-34]). This venom is similar to venom from jellyfish, bees, lizards, scorpions and snakes ([@ref-28]) with over 55- toxin related sequences including neurotoxins, cytolysins (actinoporins), toxic phopholipases and peptidases with molecular weights of 25 kDa--100 kDa ([@ref-5]) being discovered to date. Among these toxins lies HALT, which is an α-pore-forming toxin (α-PFT) identified from the genome of *Hydra magnipapillata* ([@ref-9]). HALT-1 (20.8 kDa), which is localized in stenoteles has been shown to exhibit strong haemolytic and cytolytic activity towards hematologic cells and HeLa cells ([@ref-9]; [@ref-14]). It binds on the cell membrane and lyses the targeted cell. The conserved cluster of aromatic amino acid and an amphiphilic N-terminus in HALT-1 was reported to be important in membrane binding and pore formation ([@ref-14]). Therefore, in order to further analyze the hemolytic activity of HALT-1 and its potential as a toxin moiety candidate in future immunotoxins, cytotoxic assays and immunofluorescence binding localization assays were used in this study.

Material and Methods
====================

Production, isolation and purification of recombinant wtHALT-1 and mHALT-1
--------------------------------------------------------------------------

*Hydra*'s wtHALT-1 and mHALT-1 gene sequences were previously cloned into pET28a vector and transformed into *E. coli* BL21 (DE3) for expression. Site-directed mutagenesis of wtHALT-1 was performed where tyrosine was substituted at position 110 to alanine ([@ref-14]). Both wtHALT-1 and mHALT-1 were isolated and cultured in LB broth with 50 mg/mL kanamycin at 37 °C. Subsequently, 1.0 mM of IPTG was used as an inducer for protein expression at 0.5--0.6 OD~600~. Pellets were harvested by centrifugation at 10,000 rpm and sonicated with 0.5 M phenylmethanesulfonyl fluoride (PMSF) as a protease inhibitor. Sonication was done with 130 watt, 20 kHz, at 10 s pulse on, followed by 20 s pulse off. Both recombinant His-tagged wtHALT-1 and mHALT-1 were separated from insoluble fractions by centrifugation for 10 mins at 10,000 rpm, 4 °C. Expressed recombinant proteins were then purified using His-spin trap kit (GE Healthcare, US). Binding buffer with 20 mM, 50 mM and 100 mM of imidazole were used to wash purified recombinant wtHALT-1 and mHALT-1, and eluted out with 500 mM imidazole. Subsequently, SDS-PAGE with 12% (w/v) separating gel and 5% (w/v) stacking gel were used to separate purified proteins. Pure fractions of recombinant wtHALT-1 and mHALT-1 were concentrated and desalted with PBS using Amicon^®^ Ultra-2ml centrifugal filter (Merck, Germany) at 8,000 rpm, 4 °C for 15 mins. Protein quantification was performed using Quick Start™ Bradford Assay (Bio-Rad, USA) at 595 nm.

Cell culture
------------

Seven different cell lines, HeLa (*ATCC*^®^ CCL-2™), HepG2 (*ATCC*^®^ HB-8065™), MCF-7 (*ATCC*^®^ HTB-22™), SW-620 (*ATCC*^®^ CCL-227™), HCT116 (*ATCC*^®^ CCL-247™), CCD 841 CoN (*ATCC*^®^ CRL-1790™) and normal human dermal fibroblast (NHDF) (*ATCC*^®^ PCS-201-012™) were used in this study. Each cell line was cultured in CO~2~ incubator at 37 °C and 5% CO~2~. Cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 60 mg/mL of penicillin and 100 mg/mL of streptomycin.

Cytotoxicity assay
------------------

MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay was performed to evaluate the cytotoxic effects of wtHALT-1 and mHALT-1 on different cell lines. Seven different cell lines were treated with wtHALT-1, mHALT-1, and camptothecin (1--5 µM) at different concentrations. Two controls comprising a negative control (medium only) and a positive control (camptothecin) were included in each set of assay. Cells (1 × 10^4^ cells/mL) were incubated for 24 h after the addition of wtHALT-1 and mHALT-1 at a concentration of 0.20 to 1.70 µM. Briefly, 50 µL of 10 mg/mL MTT was added to each well and incubated for 4 h at 37 °C with 5% CO~2.~ The supernatant was then removed and formazan violet crystals were dissolved by adding 200 µL of DMSO. Absorbance was measured at 570 nm using FLUOstar Omega microplate reader (BMG Labtech, Germany) and the percentage of cell viability was calculated. Each data point represents the average viability obtained from triplicate experiments. IC~50~ values were calculated using logarithmic regression analysis in Microsoft Excel.

Annexin V FITC/ PI apoptosis detection assay
--------------------------------------------

Annexin V FITC/ PI apoptosis detection assay kit (Invitrogen, USA) was used to determine the percentage of cells within a population that are actively undergoing apoptosis. In brief, cells (1 × 10^6^ cells/mL) were harvested after treatment with wtHALT-1 and camptothecin for 24 h using IC~50.~ Treatment with mHALT-1 was also carried out using the same test concentrations as wtHALT-1. Apoptosis was detected by initially staining the cells with 0.1% (v/v) Annexin V and 100 µg/mL of propidium iodide solution followed by flow cytometry analysis. Stained cell suspensions were incubated in the dark for 15 min at room temperature, 400 µL of 1×  binding buffer was added to each tube and analyzed using NovoCyte ™ 2060 flow cytometer (ACEA Biosciences, USA).

Immunofluorescence staining assay
---------------------------------

Immunofluorescence (IF) staining assay was done to visualize the cellular localization of wtHALT-1 and mHALT-1 binding. Indirect IF assay was performed using primary mouse anti-His tag antibody (ABM, Canada) and Alexa Fluor 488 goat anti-mouse IgG (H+L) secondary antibody (ThermoFisher, USA). HepG2, HeLa, MCF-7 and SW-620 cell lines were harvested after treatment with wtHALT-1, mHALT-1 and camptothecin for 24 h. Cells (1 × 10^6^ cells/mL) were washed with PBS 3 times after treatment and fixed with 4% paraformaldehyde followed by 3 more washes with PBST. Permeabilization was performed by incubating the cells with 0.1% triton X-100 for 10 min. Cells were then washed 3 times with PBS and blocked with 2% BSA for 45 mins to minimize unspecific binding. Cells were then incubated with anti-His tag primary antibody for 1 h to mark histidine-tagged proteins and washed with PBST 3 times, 5 mins each. Alexa Fluor 488 goat anti-mouse IgG (H+L) secondary antibody was then added and incubated for 1 h in the dark. Cells were then washed 3 times with PBS and stained with Hoechst 33342 solution for 10 mins as a nuclear counter stain. All images were captured and analyzed using a fluorescence microscope Axio Vert A1 (Carl Zeiss, Germany) under 630×  magnification. Fluorescence quantification was calculated using Zen software based on captured triplicate images.

Statistical analysis
--------------------

All statistical analysis was completed using Excel. Data were expressed as mean ± S.D. The statistical significance analysis was done using Student's two tailed *t*-test, and data significance levels are shown as \**p*  \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.

Results
=======

Y110A mutant HALT-1 abrogates cytotoxic effects of wild-type HALT-1 on various cell lines
-----------------------------------------------------------------------------------------

Dose dependent cytotoxic responses of wtHALT-1 and mHALT-1 on 5 cancer and 2 non-tumour cell lines are shown in [Fig. 1](#fig-1){ref-type="fig"}. Experimental results indicated that wtHALT-1 induced potent cytotoxic effects (IC~50~ range of 0.30--1.62 µM) against human cancer cell lines, including MCF-7, HeLa, HepG2, HCT116 and SW-620 ([Table 1](#table-1){ref-type="table"}). The IC~50~ of wtHALT-1 (0.51 µM) on HeLa cells was consistent with values obtained previously by ([@ref-14]) where HeLa cell viability dropped from 88% to 3% after wtHALT-1 treatment. Among all the cell lines tested, the potency of wtHALT-1 was found to be highest on MCF-7 cells with an IC~50~ value of 0.30 µM. The cytotoxic effect of wtHALT-1 was shown to be 50% stronger than mHALT-1 (*p* = 0.022) on MCF-7 cells (IC~50~ = 0.30 µM). Similar effects were observed on HepG2 (wtHALT-1 IC~50~ = 0.60 µM), where a significant reduction of mHALT-1 cytotoxicity (*p* = 0.004) was observed. The non-tumour human cell line (NHDF) also exhibited the same activity as HepG2 where viability levels were significantly higher (*p* = 0.008) at 92% after being treated with mHALT-1 in comparison to 33% with wtHALT-1 (IC~50~ of 0.52 µM). It was hypothesized that IC~50~ variations among cell lines were attributed to differences in SM distributions in the plasma membrane, which remains poorly studied to date ([@ref-16]). It was also interesting to note that IC~50~ values were higher in colorectal cell lines SW-620 (IC~50~ = 0.64 µM), HCT116 (IC~50~= 1.47 µM) and CCD841CoN (IC~50~ = 1.62 µM) in comparison to other cancer cell lines. At concentrations of 0.24, 0.48, 0.72, 0.96 and 1.20 µM of wtHALT-1, the cell viability of SW-620 were reported to be 86%, 68%, 34%, 25% and 7% respectively. Cell viability of SW-620 after treatment with mHALT-1 was significantly higher than its wild type counterpart (*p* = 0.021) with viability levels above 96%. The cytotoxicity pattern was similar on HCT116 and CCD841CoN where the viability of mHALT-1 was 2 to 3 times higher than wtHALT-1 (*p* = 0.005 and 0.039) respectively. Collectively, these results supported the notion that the Y110A mutation at the SM binding domain of mHALT-1 was successful in abrogating the cytotoxic effects of wtHALT-1.

![Comparison of cell viability on (A) CCD841CoN(B) NHDF (C) HCT116 (D)HeLa (E) HepG2 (F)MCF7 (G) SW-620 treated for 24 h with wtHALT-1 and mHALT-1.\
Data are represented as means  ± SD of three samples from three independent experiments, where (\*) indicates significant difference levels as \**p* \< 0.05, and \*\**p* \< 0.01.](peerj-07-6639-g001){#fig-1}
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###### A summary of IC~50~ values for various cell lines (1 × 10^4^ cells/mL) treated for 24 h with wtHALT-1 and mHALT-1.

![](peerj-07-6639-g005)

  **Cell lines**   **Compound**   **IC**~**50**~   ***R***^2^**value**
  ---------------- -------------- ---------------- ---------------------
  HeLa             wtHALT-1       0.51 µM          0.999
                   mHALT-1        n/a              0.722
  HepG2            wtHALT-1       0.60 µM          0.996
                   mHALT-1        n/a              0.461
  MCF-7            wtHALT-1       0.30 µM          0.999
                   mHALT-1        n/a              0.393
  SW-620           wtHALT-1       0.64 µM          0.986
                   mHALT-1        n/a              0.777
  HCT116           wtHALT-1       1.47 µM          0.969
                   mHALT-1        n/a              0.576
  NHDF             wtHALT-1       0.52 µM          0.994
                   mHALT-1        n/a              0.323
  CCD841CoN        wtHALT-1       1.62 µM          0.997
                   mHALT-1        n/a              0.820

wtHALT-1 induces apoptosis-mediated cell death
----------------------------------------------

Once HALT-1 cytotoxic properties were assessed, whether cell death was mediated by apoptosis was determined. Flow cytometry analysis with Annexin V-FITC/PI double staining was conducted where viable cells would remain unstained (Annexin V-FITC^−^/PI^−^), early apoptotic cells would be Annexin V-FITC^+^/PI^−^, whereas late apoptotic cells would exhibit a double positive Annexin V-FITC^+^/PI^+^ staining pattern due to loss of plasma membrane integrity and externalization of phosphatidylserine ([@ref-35]; [@ref-18]; [@ref-33]; [@ref-7]). Exposure to wtHALT-1 at IC~50~ on HeLa cells for 24 h demonstrated an increase in early and late apoptotic cells at 35.50% and 22.81%, respectively ([Fig. 2](#fig-2){ref-type="fig"}). In comparison, treatment with mHALT-1 yielded only 9.86% and 7.87% in early and late apoptosis (*p* = 0.164), which was consistent with preliminary MTT data. Camptothecin treated cells also demonstrated an increase in early and late apoptosis (35.96% and 19.74% respectively). Similar patterns of apoptotic induction between wtHALT-1 and mHALT-1 were also observed on MCF-7 cells ([Fig. 2](#fig-2){ref-type="fig"}). These results confirmed that wtHALT-1 triggered cell death via an apoptosis-induced mechanism, albeit the type of apoptotic pathways involved remains unknown at present. However, the observed effects of wtHALT-1 on HepG2 were skewed more towards the necrotic population, presumably due to delayed post-treatment assay timing. As shown in [Fig. 2](#fig-2){ref-type="fig"}, we noticed around 40% of untreated HepG2 had necrotic cells. It was also noteworthy that apoptotic effects were found to be inconsistent on SW-620 cells where mHALT-1 showed 7.12% higher levels of apoptotic cells than wtHALT-1 even after the membrane binding affinity was removed, possibly indicating that mHALT-1 is capable of binding to other membrane markers unique to this cell line with relatively low affinity in addition to sphingomyelin-based recognition.

![Annexin V/FITC-PI flow cytometry analysis of various cancer cells (1 × 10^6^ cells/mL) treated with negative control, wtHALT-1,mHALT-1 and camptothecin for 24 h.\
Cells were dual stained with Annexin V-FITC and propidium iodide, and the dot plot of HeLa, HepG2, MCF-7 and SW-620 with different treatments were shown. Each set of data shown are a representative plot of three independent experiments, while percentages are the mean value of three independent experiments.](peerj-07-6639-g002){#fig-2}

Loss of wtHALT-1 membrane bound SM affinity on various cell lines following Y110A mutation
------------------------------------------------------------------------------------------

In order to study the localization of wtHALT-1 and mHALT-1, immunofluorescence staining was performed on HeLa, HepG2, MCF-7 and SW-620 cells. Different cell lines were incubated with different IC~50~ of wtHALT-1, mHALT-1 and camptothecin for 24 h followed by labeling with anti-His tag antibodies and stained fluorescently with Alexa Fluor 488-conjugated goat anti-mouse IgG (H+L) antibody. A significant difference between wtHALT-1 and mHALT-1 binding treatment was clearly observed where emission of green fluorescence along the cell membrane was observed only in the former ([Fig. 3](#fig-3){ref-type="fig"}). Additionally, the occurrence of apoptosis on various cell lines after wtHALT-1 treatment and camptothecin treatment was also evident through cell morphological changes and nuclear condensation ([Fig. 3](#fig-3){ref-type="fig"}). Relative fluorescence intensity for each cell line was normalized with the negative untreated control as depicted in [Fig. 4](#fig-4){ref-type="fig"}. Relative fluorescence intensity upon treatment with mHALT-1 showed 0.12 fold reduction in comparison to wtHALT-1 treated HeLa cells. The biggest reduction of relative fluorescence intensity was observed on HepG2 cells, with a 41.6% reduction in mHALT-1 compared to wtHALT-1 treatment. Fluorescence intensity patterns in MCF-7 and SW-620 were also consistent between HeLa and HepG2 cells where a general reduction was observed between wtHALT-1 and mHALT-1, thus reaffirming the success of Y110A mutants in neutralizing binding capabilities of HALT-1.

![Immunofluoroscence images of cell lines treated with wtHALT-1, mHALT-1 and camptothecin for 24 h.\
Cells were stained with anti- His tag antibody (1:200) and stained immunofluoroscently with Alexa Fluor 488 goat anti-mouse IgG (H+L) antibody (1:3,000 dilutions) (green). Nuclei were counterstained with Hoechst dye (blue). Images were obtained on an Axio Vert A1 under 630×  magnification and arranged with Zen software, Adobe photoshop CC editor, and FotoJet. Red arrows indicate HALT-1 binding while arrow head indicate apoptotic cells. Scale bars: 20 µM. Each set of data shown are representative profile of three independent experiments.](peerj-07-6639-g003){#fig-3}

![Quantification of immunofluorescent staining.\
HeLa, HepG2, MCF7 and SW-620 cell lines were seeded at 1 × 10^4^ cells/well in 96-well plates. Cell lines were treated with wtHALT-1, mHALT-1 and camptothecin at IC~50~ values. Fluorescence signal intensities were quantified with the Zen software and presented as mean values from triplicate experiments.](peerj-07-6639-g004){#fig-4}

Discussion
==========

In this study, wtHALT-1 was expected to bind to almost all cell lines tested, while a point mutation in wtHALT-1 at Y110A position was hypothesized to disable the toxin's recognition capabilities towards human cell membranes. This is critical because as an immunotoxin candidate it should only bind specially to the targeted cells when coupled with an antibody or an equivalent targeting moiety. Actinoporins including HALT-1 are conserved in their structure where beta-sheets are sandwiched by two alpha-helices. Crystallographic study of fragaceatoxin C (sea anemone actinoporin) demonstrated van der Waals and nonpolar interactions between valine 60 (of one protomer) and phenylalanine 163 (of another protomer), and this bonding contributes to dimerization or oligomerization ([@ref-22]). These two residues are positioned distantly from tyrosine 110 in the 3D crystal structure, suggesting that tyrosine 110 does not play a role in oligomerization. Moreover, substitution of tyrosine 110 with alanine removes the benzene ring instead of introducing bulky groups, which may affect the protein structure. In a recent study, tyrosine at position 110 of HALT-1 was predicted to be crucial for sphingomyelin recognition and binding ([@ref-14]). Site directed mutagenesis removed the aromatic ring of the tyrosine amino acid essential for membrane recognition, and was performed previously producing the mHALT-1 variant used in this study ([@ref-4]). Assessment on 7 cell lines in this study has demonstrated that wtHALT-1 significantly reduces cell viability at a lower IC~50~ compared to mHALT-1. Results in [Fig. 1](#fig-1){ref-type="fig"} showed that more than 50% of cells were non-viable after 24 h of treatment, comparable to [@ref-9] data, thus confirming the cytotoxic properties of wtHALT-1. This study indicates that mutants harbouring a single substitution from tyrosine to alanine reduces the cytotoxic activity of wtHALT-1 consistent with the result of [@ref-14] who reported that HALT-1 reduced the viability of HeLa cells by 50% at 15 µg/mL but was maintained at more than 80% when treated with mHALT-1. It was hypothesized that the loss of its membrane binding ability was responsible for its inability to permeabilize the cell membrane to create pores.

Although wtHALT-1 showed cytotoxic effects on different cancer cell lines, it was not clear how this toxin induced cell death once introduced to cancer cell lines. In this study, results obtained from Annexin V FITC/PI apoptosis assay on four out of the five cancerous cell lines with low IC~50~ values revealed that cytotoxicity was triggered via an apoptosis-mediated cell death mechanism. These results are further supported by [@ref-12] which reported ß-PFT toxins derived from sea anemone *Phyllodiscus semoni* and *Actinaria villosa* were also capable of initiating apoptotic cell death pathways. Even though the annexin V-FITC/PI staining method has been well established, this method still suffers from several limitations in accurately measuring cells that have died of apoptosis versus necrosis. An example of this limitation is when the end point measurement is conducted exceeding the apoptotic window period, as apoptotic cells also lose membrane permeability in the later stages of apoptosis due to severe membrane damage, as was observed with HepG2 cells. Another noteworthy limitation with this assay when investigating pore forming toxins such as HALT-1 is the enhanced influx of PI into cells when pores are formed following wtHALT-1 binding, which can compromise the quantification of cell death between treatment groups.

While numerous experiments have supported the critical role for SM as the membrane attachment site for sea anemone actinoporins ([@ref-4]) some reports suggest otherwise. A similar result was obtained with another actinoporin sticholysin of *Stichodactyla helianthus,* which was able to permeabilize large unilamellar vesicles (LUVs) composed of cholesterol and phosphatidylcholine in addition to SM ([@ref-23]; [@ref-15]; [@ref-13]). Another recent study also reported the folate receptor alpha as an interaction partner of HALT-1, which served as an alternative to the previously established binding of HALT-1 to the lipid SM ([@ref-1]). Therefore, further developmental efforts may be required to ascertain whether optimization through additional point mutations at other binding domains of mHALT-1 are required to completely neutralize its binding properties, hence transitioning it into a promising toxin moiety candidate.

Conclusions
===========

In conclusion, the results of this investigation confirm the potential for mHALT-1 with a Y110A point substitution mutation as a potential toxin moiety candidate capable of inducing apoptosis for the development of future immunotoxins as a form of targeted therapy.
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###### Cell viability of (A) MCF-7 (B) HeLa treated for24, 48 and 72 h with camptothecin as positive control.

Data are represented as means ±SD from three independent experiments.

###### 

Click here for additional data file.
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###### Time course comparison of cell viability for (A)MCF-7 (B) HeLa treated for 48 and 72 h with wtHALT-1 and mHALT-1.

Data are represented as means ± SD from three independent experiments, where (\*) indicates significant difference levels as \**p* \< 0.05, and \*\**p* \< 0.01.

###### 

Click here for additional data file.
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###### A summary of IC~50~ values for MCF-7and HeLa cell lines (1 × 10^4^ cells/mL) treated for 24, 48 and 72 h with camptothecin as positive control, wtHALT-1 and mHALT-1.

###### 

Click here for additional data file.

10.7717/peerj.6639/supp-4

###### Absorbance reading for wtHALT-1, mHALT-1 and campthothecin on CCD841CoN cells

Minus blank is average value of each concentration subtracted with average of blank. Standard deviation is standard error calculated from the three readings.

###### 

Click here for additional data file.
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###### Absorbance reading for wtHALT-1, mHALT-1 and camptothecin on HepG2 cells

Minus blank is average value of each concentration subtracted with average of blank. Standard deviation is standard error calculated from the three readings.

###### 

Click here for additional data file.
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###### Absorbance reading for wtHALT-1, mHALT-1 and camptothecin on MCF-7 cells

Minus blank is average value of each concentration subtracted with average of blank. Standard deviation is standard error calculated from the three readings.

###### 

Click here for additional data file.
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###### Absorbance reading for wtHALT-1, mHALT-1 and camptothecin on HeLa cells

Minus blank is average value of each concentration subtracted with average of blank. Standard deviation is standard error calculated from the three readings.

###### 

Click here for additional data file.
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###### Absorbance reading for wtHALT-1, mHALT-1 and camptothecin on HCT116 cells

Minus blank is average value of each concentration subtracted with average of blank. Standard deviation is standard error calculated from the three readings.

###### 

Click here for additional data file.
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###### Absorbance reading for wtHALT-1, mHALT-1 and camptothecin on NHDF cells

Minus blank is average value of each concentration subtracted with average of blank. Standard deviation is standard error calculated from the three readings.

###### 

Click here for additional data file.
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###### Absorbance reading for wtHALT-1, mHALT-1 and camptothecin on SW-620 cells

Minus blank is average value of each concentration subtracted with average of blank. Standard deviation is standard error calculated from the three readings.

###### 

Click here for additional data file.
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###### Analysis of HeLa cells ( 1 × 10^6^ cells/mL)

HeLa cells were treated with negative control (untreated HeLa), wtHALT-1, mHALT-1 and camptothecin for 24 h. Cells were stained with Annexin V-FITC and propidium iodide. Dot plot of HeLa with different treatments were shown as three independent experiments.

###### 

Click here for additional data file.
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###### Analysis of HepG2 cells ( 1 × 10^6^ cells/mL)

HepG2 cells treated with negative control (untreated HepG2), wtHALT-1, mHALT-1 and camptothecin for 24 h. Cells were stained with Annexin V-FITC and propidium iodide. Dot plot of HepG2 with different treatments from three independent experiments were shown.

###### 

Click here for additional data file.
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###### Analysis of SW-620 cells ( 1 × 10^6^ cells/mL)

SW-620 cells were treated with negative control (untreated SW-620), wtHALT-1, mHALT-1 and camptothecin for 24 h. Cells were stained with Annexin V-FITC and propidium iodide. Dot plot of SW-620 with different treatments from three independent experiments were shown.

###### 

Click here for additional data file.
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###### Analysis of MCF-7 cells ( 1 × 10^6^ cells/mL)

MCF-7 cells were treated with negative control (untreated MCF-7), wtHALT-1, mHALT-1 and camptothecin for 24 h. Cells were stained with Annexin V-FITC and propidium iodide. Dot plot of MCF-7 with different treatments from three independent experiments were shown.

###### 

Click here for additional data file.
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###### Percentage of apoptosis-inducing effects on various cancer cell lines

*p*-values presented were obtained using two-tailed *t*-test by comparing wtHALT-1 and mHALT-1 on various cell lines. Data significance levels were shown as \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001.

###### 

Click here for additional data file.
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###### Immunofluorescence images of HeLa cells. \<!--\[if !mso\]--\>\<!--\[endif\]--\>\<!--\[if !mso\]--\>\<!--\[endif\]--\>\<!--\[if !mso\]--\>\<!--\[endif\]--\>\<!--\[if !mso\]--\>\<!--\[endif\]--\>\<!--\[if !mso\]--\>\<

HeLa cells were treated with wtHALT-1, mHALT-1 and camptothecin for 24 h. Cells were stained with anti- His tag antibody (1:200) and stained immunofluorescently with Alexa Fluor 488 goat anti-mouse IgG (H+L) secondary antibody (1:3,000 dilutions) (green). Nuclei were counterstained with Hoechst dye (blue). Images were obtained on an Axio Vert A1 under 630×magnification and arranged with Zen software, Adobe photoshop CC editor, and FotoJet. White arrows indicate HALT-1 binding while arrow head indicate apoptotic cells. Scale bars: 20 µm. Each set of data shown are representative profile of three independent experiments.

###### 

Click here for additional data file.
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###### Immunofluorescence images of HepG2 cells

HepG2 cells were treated with wtHALT-1, mHALT-1 and camptothecin for 24 h. Cells were stained with anti- His tag antibody (1:200) and stained immunofluorescently with Alexa Fluor 488 goat anti-mouse IgG (H+L) antibody (1:3,000 dilutions) (green). Nuclei were counterstained with Hoechst dye (blue). Images were obtained on an Axio Vert A1 under 630×magnification and arranged with Zen software, Adobe photoshop CC editor, and FotoJet. White arrows indicate HALT-1 binding while arrow head indicate apoptotic cells. Scale bars: 20 µm. Each set of data shown are representative profile of three independent experiments.

###### 

Click here for additional data file.
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###### Immunofluorescence images of MCF-7 cells

MCF-7 cells were treated with wtHALT-1, mHALT-1 and camptothecin for 24 h. Cells were stained with anti- His tag antibody (1:200) and stained immunofluorescently with Alexa Fluor 488 goat anti-mouse IgG (H+L) antibody (1:3,000 dilutions) (green). Nuclei were counterstained with Hoechst dye (blue). Images were obtained on an Axio Vert A1 under 630×magnification and arranged with Zen software, Adobe photoshop CC editor, and FotoJet. White arrows indicate HALT-1 binding while arrow head indicate apoptotic cells. Scale bars: 20 µm. Each set of data shown are representative profile of three independent experiments.

###### 

Click here for additional data file.
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###### Immunofluoroscence images of SW-620 cells

SW-620 cells were treated with wtHALT-1, mHALT-1 and camptothecin for 24 h. Cells were stained with anti- His tag antibody (1:200) and stained immunofluoroscently with Alexa Fluor 488 goat anti-mouse IgG (H+L) antibody (1:3,000 dilutions) (green). Nuclei were counterstained with Hoechst dye (blue). Images were obtained on an Axio Vert A1 under 630×magnification and arranged with Zen software, Adobe photoshop CC editor, and FotoJet. Red arrows indicate HALT-1 binding while arrow head indicate apoptotic cells. Scale bars: 20 µm. Each set of data shown are representative profile of three independent experiments.

###### 

Click here for additional data file.

10.7717/peerj.6639/supp-20

###### Fluorescence intensity of various cancer cell lines

*p*-values presented were obtained using two-tailed *t*-test by comparing wtHALT-1 and mHALT-1 on HeLa cells. Data significance levels were shown as \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001.

###### 

Click here for additional data file.
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